Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

is.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively m
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Rosa & Co. LLC, a drug development advisory ... today announced it has two posters scheduled to be ... and Therapeutics meeting in New Orleans, LA ... - http://photos.prnewswire.com/prnh/20150302/179058LOGO   Bristol- Myers ... a quantitative systems pharmacology approach for immuno-oncology drug development ...
(Date:3/3/2015)... 03, 2015 Cambridge Semantics, the leading ... technology, today announced that it has been named to ... in Knowledge Management.’ , To create the list ... analysts and system integrators who identify organizations dedicated to ... right information to the right people at the right ...
(Date:3/3/2015)... , March 3, 2015 ... tools for implementing competency-based training to comply with new ... is offering a new crosswalk tool ... implement competency-based training for direct service workers as a ... Medicaid Services (CMS) regulations. CMS amended the ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario ... a biomedical researcher and founding partner of Criogenix SA ... of biomedical professors who will teach the “Diplomat in ... de CV is a private company registered in the ... in Mexico (RENIECYT). , Camacho Alcocer will teach two-day, ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... 2012  Agendia, an innovative molecular cancer diagnostics company, ... contract with Blue Shield of California, making Agendia ... for future in-network coverage for MammaPrint® and other ... United States. Developed and commercialized by Agendia, MammaPrint ...
... Jan. 5, 2012 CMC Biologics, a leading ... European Patent No. US 2,171,034 B1 covering a ... mammalian cell culture bioreactors. The invention is designed ... continuous perfusion fermentation process, wherein the bioreactor (fermenter) ...
... (Nasdaq: NKTR ) President and Chief Executive Officer, ... 30th Annual J.P. Morgan Healthcare Conference in San Francisco at ... at 8:30 a.m. Pacific time. The presentation will ... the Investor Relations, Events Calendar section of the Nektar website: ...
Cached Biology Technology:Agendia Signs Contract with Blue Shield of California 2CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems 2Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... Iowa State University researchers have developed a technology that ... cervical cancer in women. Thats a significant improvement ... Edward Yeung, an Iowa State Distinguished Professor and the ... research team that developed the new test. The current ...
... percent increase in lifespan, raising the tantalizing question of ... taking an anti-aging medication. Results of the Buck Institute ... are currently published online in the Journal of Biological ... mood affective disorders, including bipolar disease for decades. While ...
... Monmouth University,s Urban Coast Institute will host its ... 2007, from 10 a.m. to 12 p.m., in the ... an Ocean Literate Society: Building Communities for Action," will ... of communication will be used to increase the general ...
Cached Biology News:Iowa State researchers develop technology for early detection of viruses 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Abel to receive posthumous Ocean and Coastal Leadership award 2
The filter 640DF35 for the Molecular Imager FX is a band pass filter for Texas Red dye....
... APO-BRDU Kit is a 2-color staining method ... DNA to detect apoptotic cells by flow ... reagents required for measuring apoptosis in cells, ... assessing reagent performance; washing, reaction and rinsing ...
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Model 175 tube gel cell is a ... for 2-D electrophoresis applications. The upper buffer ... tubes 9-23 cm long for isoelectric focusing ... buffer chamber and cooling core, lower buffer ...
Biology Products: